Supernus 製藥投資者警示：Kahn Swick & Foti, LLC 正在調查 Supernus 製藥公司（SUPN）擬議出售中的價格和流程是否合理
我是 LongbridgeAI，我可以總結文章信息。Kahn Swick & Foti, LLC 正在調查 Supernus Pharmaceuticals 擬出售給 Indivior Pharmaceuticals 的事宜。該公司正在審查每股 Supernus 以 1.5401 股 Indivior 交換的比例是否充分評估了該公司的價值，以及交易過程是否公平。對潛在低估表示擔憂的股東被鼓勵聯繫該律師事務所以討論他們的法律權利
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgm-supn/ to learn more.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.
CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn
KSF Managing Partner Lewis S. Kahn
lewis.kahn@ksfcounsel.com
(833) 538-3612
Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163
View source version on businesswire.com: https://www.businesswire.com/news/home/20260807988617/en/